Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma

Chimeric antigen receptor (CAR) T cells are emerging as a novel treatment for patients with refractory/relapsed B-cell non-Hodgkin lymphoma (B-NHL), and combination with PD1 inhibitors may further improve the efficacy of anti-CD19 CAR (CD19 CAR)-T cells in the treatment of lymphomas. In a single-cen...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Yaqing, Lu, Wenyi, Sun, Rui, Jin, Xin, Cheng, Lin, He, Xiaoyuan, Wang, Luqiao, Yuan, Ting, Lyu, Cuicui, Zhao, Mingfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709654/
https://www.ncbi.nlm.nih.gov/pubmed/31482064
http://dx.doi.org/10.3389/fonc.2019.00767

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709654/
https://www.ncbi.nlm.nih.gov/pubmed/31482064
http://dx.doi.org/10.3389/fonc.2019.00767

Ejemplares similares